Contineum Therapeutics (CTNM) Q1 2026 earnings summary

Executive summary

• Clinical-stage biopharma focused on neuroscience, inflammation, and immunology (NI&I) with two lead drug candidates: PIPE-791 (wholly owned) and PIPE-307 (partnered with J&J/Janssen).

• PIPE-791 is in Phase 2 for idiopathic pulmonary fibrosis (IPF) with patient dosing initiated for a 324-patient global trial, and has shown positive Phase 1b data for chronic pain, meeting safety and efficacy objectives.

• PIPE-307 is in Phase 2 for major depressive disorder (MDD) with the Moonlight-1 trial underway and completed Phase 2 for RRMS, though efficacy endpoints were not met.

• No product revenue; operations funded by equity offerings and a $50M upfront payment from J&J.

• Cash runway projected through mid-2029, extending about one year past estimated IPF trial completion.

Financial highlights

• Net loss of $14.5M for Q1 2026, improved from $16.0M in Q1 2025; net loss per share was $0.39 with 37.3M weighted-average shares outstanding.

• Research and development expenses decreased to $11.6M, down 15% year-over-year, mainly due to lower CRO and toxicology costs.

• General and administrative expenses increased to $5.3M, up 20% year-over-year, driven by higher stock-based compensation and personnel costs.

• Interest income rose to $2.5M from $2.3M due to higher invested balances.

• Cash, cash equivalents, and marketable securities totaled $246.3M as of March 31, 2026.

Outlook and guidance

• Cash resources are expected to fund planned operations for at least 12 months from the reporting date and through mid-2029.

• Operating expenses projected to increase as clinical and preclinical programs advance and headcount grows.

• Additional financing may be required for future development and commercialization; potential sources include equity, debt, or strategic partnerships.

• Disciplined capital allocation prioritizing lead clinical indication while considering advancement of other programs.